Targeting the NMDA Glutamate Receptor as Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression

Trial Profile

Targeting the NMDA Glutamate Receptor as Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2016 Status changed from recruiting to completed.
    • 04 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 09 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top